ライフサイエンスコーパス: pharmacogenetics

1 could link to normal reversal learning using pharmacogenetics.

2 hism is one of the most 'mature' examples in pharmacogenetics.

3 This field is referred to as pharmacogenetics.

4 ed, another factor that could influence SULT pharmacogenetics.

5 asic research and in clinical application of pharmacogenetics.

6 g example of the potential clinical value of pharmacogenetics.

7 ional mechanisms not previously described in pharmacogenetics.

8 tility for linkage-disequilibrium mapping in pharmacogenetics.

9 s, developmental regulation, toxicology, and pharmacogenetics.

10 , illustrates the promise and limitations of pharmacogenetics.

11 d theories of biogenic amine dysfunction and pharmacogenetics.

12 tcomes, which are of particular relevance in pharmacogenetics.

13 mechanism of action will lead to advances in pharmacogenetics.

14 foods remain to be evaluated in light of CYP pharmacogenetics.

15 h particular design features of relevance in pharmacogenetics.

16 l implementation of clopidogrel and warfarin pharmacogenetics.

17 edicine, and future clinical implications of pharmacogenetics.

18 obehavioral mechanisms of naltrexone and its pharmacogenetics.

19 with, previous findings in antihypertensive pharmacogenetics.

20 We provide a current review of opiate pharmacogenetics.

21 (4) genetics/gene-environment interactions, pharmacogenetics; (5) intervention/prevention/therapeuti

22 The marked racial differences in relevant pharmacogenetics, a potential explanation for differing

23 important implications in the application of pharmacogenetics across a range of common diseases, incl

24 Pharmacogenetics aims to identify individuals predispose

25 Pharmacogenetics analysis showed single nucleotide polym

26 Pharmacogenetics analysis showed that exm-rs1321744 achi

27 or candidate gene association studies, 5 for pharmacogenetics and 21 for biochemical studies.

28 ncluding histocompatibility, immunogenetics, pharmacogenetics and anthropology studies, among many ot

29 Large-scale pharmacogenetics and complex disease association studies

30 describe recent advances in antihypertensive pharmacogenetics and discuss challenges related to trans

31 use of SNPs in such diverse applications as pharmacogenetics and genome-wide association studies for

32 This review will focus on pharmacogenetics and pharmacogenomics and their role in

33 It is clear that progress in the field of pharmacogenetics and pharmacogenomics will help further

34 f AA in patients treated with TNF inhibitors.Pharmacogenetics and the inherent physiologic levels of

35 First, using pharmacogenetics and two-photon calcium imaging, we vali

36 ating that each group has different warfarin pharmacogenetics and would benefit from genotype-based d

37 Pharmacogenetics and, more recently, pharmacogenomics ha

38 ocompatibility, immunology, epidemiology and pharmacogenetics) and population genetics.

39 clinical pharmacology, pharmacokinetics and pharmacogenetics, and biostatistics and a patient repres

40 n microscopy, morphological reconstructions, pharmacogenetics, and diffusible dye, calcium, and gluta

41 ion--including gene-environment interaction, pharmacogenetics, and genetic counseling--are also discu

42 We discuss metformin, OCT1, pharmacogenetics, and how the integrative genomics revol

43 road implications for personalized medicine, pharmacogenetics, and the meaning of race.

44 ate with advances in genetics, genomics, and pharmacogenetics; and how they can apply this knowledge

45 This study's pharmacogenetics approach strongly implicates the role o

46 erapy response, current candidate gene-based pharmacogenetics approaches require a priori knowledge a

47 REVIEW: The fields of clinical genetics and pharmacogenetics are rapidly expanding.

48 me disease entities, and more will follow as pharmacogenetics becomes increasingly accepted as an imp

49 y provides the first demonstration that host pharmacogenetics can influence therapeutic response in C

50 nes from participants of the Cholesterol and Pharmacogenetics (CAP) simvastatin clinical trial, we fo

51 ved from participants in the Cholesterol and Pharmacogenetics (CAP) study who were treated with simva

52 This novel finding in N-acetylation pharmacogenetics clearly demonstrates a direct link betw

53 Coriell populations and a large ontology of pharmacogenetics concepts.

54 arin were obtained at International Warfarin Pharmacogenetics Consortium (IWPC) sites and the Univers

55 ntries as part of the International Warfarin Pharmacogenetics Consortium effort.

56 he recently published International Warfarin Pharmacogenetics Consortium pharmacogenetic-based warfar

57 Rapid advances in pharmacogenetics, continuous decrease in genotyping cost

58 parameters, drug interaction parameters, and pharmacogenetics data have been unevenly collected in di

59 g these barriers to routine incorporation of pharmacogenetics data into clinical care.

60 benefits of evolving the schema for storing pharmacogenetics data: ontologies perform well in early

61 ief review, we trace the historical roots of pharmacogenetics, discuss its rapidly evolving processes

62 The current enthusiasm for pharmacogenetics draws much of its inspiration from the

63 in the complement factor H (CFH) gene have a pharmacogenetics effect on the anti-vascular endothelial

64 For example, emerging research in pharmacogenetics explores how genetic variation in drug-

65 Pharmacogenetics explores the genetic underpinnings of v

66 ch for PD and highlight the applicability of pharmacogenetics for enhancing cellular signaling in rep

67 ns, but also for routine DNA diagnostics and pharmacogenetics for templates with different annealing

68 hould focus on reasons-perhaps compliance or pharmacogenetics-for those differences.

69 al clinical importance of the translation of pharmacogenetics from bench to bedside, the potential fo

70 Pharmacogenetics genetically re-engineers neurons to pro

71 n a few small studies relating to the use of pharmacogenetics-guided dosing in the initiation of warf

72 RECENT FINDINGS: Evidence now suggests that pharmacogenetics has a role in the effects of analgesic,

73 Recent research in antihypertensive pharmacogenetics has added to the existing evidence base

74 The importance of host pharmacogenetics has also been recognised.

75 Pharmacogenetics has been most commonly used in studies

76 Pharmacogenetics has been promoted as potentially provid

77 also summarize recent studies in which TPMT pharmacogenetics has enhanced our understanding of molec

78 Since its first description, the field of pharmacogenetics has expanded to study a broad range of

79 Pharmacogenetics has led to the identification of severa

80 oncology, systematic application of efficacy pharmacogenetics has not been integrated into drug disco

81 Pharmacogenetics has offered compelling evidence toward

82 Pharmacogenetics has the potential to complement therape

83 Over the past half century, pharmacogenetics has--like all of medical genetics--evol

84 The third area, pharmacogenetics, has utility for some therapies today.

85 ic cells and hosts (eg, pharmacokinetics and pharmacogenetics) have pushed the cure rate of childhood

86 TPMT pharmacogenetics highlights the potential clinical impor

87 Pharmacogenetics holds great promise for the optimizatio

88 integration of research on neuroimaging and pharmacogenetics holds promise for improving treatment f

89 techniques, such as excitability studies and pharmacogenetics, holds promise in elucidating the under

90 Pharmacogenetics identifies the likelihood of adverse ev

91 cogenomics Research Network and the Clinical Pharmacogenetics Implementation Consortium are partnersh

92 define the role of clopidogrel and warfarin pharmacogenetics in clinical practice.

93 gms, and look towards future applications of pharmacogenetics in enhancing the efficiency of the drug

94 y, the potential implications of transporter pharmacogenetics in influencing drug bioavailability are

95 ew Orleans in October 2012, Optogenetics and Pharmacogenetics in Neuronal Function and Dysfunction, b

96 carried out to characterize the role of UGT pharmacogenetics in several types of cancer, and these e

97 hese studies highlight the potential role of pharmacogenetics in the design of a therapeutic plan whi

98 drug pharmacokinetics, pharmacodynamics, and pharmacogenetics in view of the absence of easily measur

99 Pharmacogenetics in warfarin clinical trials have failed

100 ement strategies based on modifier genes, to pharmacogenetics, in which individual genetic informatio

101 In this article, we provide an overview of pharmacogenetics, including pharmacokinetics (PK), pharm

102 tandardized dose escalation, and to evaluate pharmacogenetics influences on PK and PD parameters.

103 esearch paradigms may be needed to translate pharmacogenetics into clinical tools.

104 antras of scientists working in the field of pharmacogenetics is 'the right dose for the right patien

105 ization of chemotherapy through the study of pharmacogenetics is becoming an ever attainable reality.

106 A synthesis of opto- and pharmacogenetics is beginning to reveal how various inte

107 Pharmacogenetics is being used to develop personalized t

108 Pharmacogenetics is one example of how gene-environment

109 Pharmacogenetics is the study of the role of inheritance

110 Pharmacogenetics is the variability of drug response due

111 The Pharmacogenetics Knowledge Base contains genomic, phenot

112 hesia and analgesia generated some hope that pharmacogenetics may guide anesthesiologists to provide

113 variants for monitoring treatment response (pharmacogenetics) may usher in a new era of personalized

114 beginning to make inroads in gastric cancer pharmacogenetics, mostly through small, pilot retrospect

115 II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391,

116 atric Asthma Gene Environment Study, and the Pharmacogenetics of Adrenal Suppression with Inhaled Ste

117 While recent advances in pharmacogenetics of adverse drug reactions show promise,

118 Although preliminary work on the pharmacogenetics of alcoholism and its treatment has bee

119 Research into the genetics and pharmacogenetics of asthma and into the societal factors

120 med a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medic

121 As a first step toward studying the pharmacogenetics of cancer chemotherapy, 51 candidate ge

122 rther research into genetic risk factors and pharmacogenetics of cardiovascular disease associated wi

123 namics (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irri

124 In conclusion, pharmacogenetics of CFH Y402H polymorphism may play a ro

125 rge transfusion requirements and the complex pharmacogenetics of clopidogrel may have played a role.

126 will discuss the most recent developments in pharmacogenetics of commonly used perioperative medicati

127 Pharmacogenetics of drug-metabolizing systems continues

128 stigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected

129 eliminary results of this pilot study on the pharmacogenetics of FcgammaR and biological therapy in p

130 We set out to study the pharmacogenetics of human arsenic methyltransferase (AS3

131 We summarize recent progress in the pharmacogenetics of IBD with respect to partitioning pat

132 The pharmacogenetics of methotrexate (MTX) was investigated

133 Initial research into the pharmacogenetics of psychotropic drug response suggests

134 dependence; however, less is known about the pharmacogenetics of smoking cessation.

135 ies to characterize the pharmacodynamics and pharmacogenetics of TAS-103 are warranted.

136 ype 3 receptor antagonists and the impact of pharmacogenetics on postoperative nausea and vomiting.

137 We review the impact of pharmacogenetics on therapy in diseases of the colon usi

138 to describe what has heretofore been called pharmacogenetics or chemicogenetics.

139 ic ligand--GPCR pairs (aka DREADDs, RASSLS, 'pharmacogenetics') permits the study of pharmacology usi

140 Pharmacogenetics (PG) could improve dosing efficiency an

141 l implementation of clopidogrel and warfarin pharmacogenetics possible.

142 Pharmacogenetics primarily uses genetic variation to ide

143 As part of a pharmacogenetics project, we screened exons and flanking

144 ion has also increased to include aspects of pharmacogenetics relating to pharmacokinetics and pharma

145 nd effect modifiers, and suggest avenues for pharmacogenetics research in the area of smoking cessati

146 t information, are tailored for leading-edge pharmacogenetics research.

147 We collected genetic data from two pharmacogenetics resequencing studies, and formulated qu

148 such unpredictability, defining the field of pharmacogenetics (see Glossary).

149 In the realm of cardiovascular pharmacogenetics, significant advances have identified m

150 5 genes play an especially important role in pharmacogenetics, since they metabolize >50% of the drug

151 MT) is one of the most developed examples of pharmacogenetics, spanning from molecular genetics to cl

152 Pharmacogenetics studies are the platform for discoverin

153 Genetic sequence data for pharmacogenetics studies can be complex, and the best in

154 rom non-responders via genetic predictors in pharmacogenetics studies have not met their anticipated

155 mine treatment in a prospective double-blind pharmacogenetics study in first-generation Mexican Ameri

156 ed by Genetic Haplotype Markers) study was a pharmacogenetics study of statin efficacy and safety.

157 This is the largest and most comprehensive pharmacogenetics study to date examining clinical respon

158 Pharmacogenetics testing in patients may help differenti

159 Pharmacogenetics, though presently confined to the asses

160 For pharmacogenetics to deliver on its potential, this compl

161 search into the role of pharmacokinetics and pharmacogenetics to guide appropriate dosing of obese pa

162 extension of previous studies of naltrexone pharmacogenetics to individuals of Asian descent, an eth

163 There are continued efforts with pharmacogenetics to predict response and side-effect ris

164 ngs, two-photon microscopy, optogenetics and pharmacogenetics to show how repeated cocaine exposure a

165 gly popular, predominantly in the context of pharmacogenetics, where the survival endpoint could be d

166 Pharmacogenetics will complement but not replace traditi

167 Ultimately, pharmacogenetics will give providers the options for imp

168 Future utility for pharmacogenetics will wax or wane depending on the natur

169 Optogenetics with microbial opsin genes, and pharmacogenetics with designer receptors, represent pote